Secukinumab NCT07704190 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 4

Clinical phase

Not yet recruiting

Recruitment status

100

Planned enrollment

2028-12-31

Primary-completion proxy

Executive view

NCT07704190 evaluates Secukinumab in Diabetes Mellitus, Type 2. The disclosed sponsor is Peking University Third Hospital, the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is Time to First Occurrence of 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), assessed over From randomization up to 2 years.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07704190 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Diabetes Mellitus, Type 2 landscape. Drug & Asset MCP drug_fetch was queried for Secukinumab, while Company & Deal Intelligence MCP organization_fetch was queried for Peking University Third Hospital.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07704190	Secukinumab	Phase 4 / Not yet recruiting	Peking University Third Hospital	Geography not reported	Time to First Occurrence of 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardi… From randomization up to 2 years	2028-12-31
PACTR202607678798356	Febuxostat	Not Applicable / Complete	Sponsor not reported	Egypt		Timing not reported
TCTR20260721005	Ferrous Sulfate/Ascorbic Acid	Phase 3 / Recruiting	Navamindradhiraj University	Thailand		2027-04-30
ISRCTN16119881	Erythropoietin(Xiamen Amoytop Biotech Co. Ltd.)	Not Applicable / No longer recruiting	Sponsor not reported	China		2024-06-30
NCT07694544	EC-5026	Phase 1 / Recruiting	Eicosis Human Health, Inc.	United States	Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) 14 days	2026-12-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07704190 is a Phase 4, not yet recruiting study with 100 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Time to First Occurrence of 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)” over “From randomization up to 2 years.” No additional primary-endpoint description was returned in the selected field set.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 100 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Diabetes Mellitus, Type 2. These records do not establish direct evidence for NCT07704190 unless the registration number matches.

Hydroxychloroquine for the Management of CVD in CKD

Phase 2; n=100; Baseline(Mean) = 1674.38 mm3 (Standard Deviation, 439.89); Baseline(Mean) = 1498.57 mm3 (Standard Deviation, 341.54) Source: https://clinicaltrials.gov/ct2/show/results/NCT03636152

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C…

Phase 2; n=143; Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median) = -14.8 Time-Averaged Percent Change in hsCRP (Inter-Quartile Range, -35.8 to 17.4); Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median): Median Difference (Net) = -59.817(95% CI, -79.690 to -39.943), P-Value = <0.0001; Median Difference (Net)… Source: https://clinicaltrials.gov/ct2/show/results/NCT06362759

Finerenone in Persons with Chronic Kidney Disease without Diabetes

Phase 3; n=1584; eGFR(mean annual rate of change) = -4.0 ml/min/1.73 m2 ( -4.3 to -3.8); eGFR(mean annual rate of change) = -3.3 ml/min/1.73 m2 ( -3.6 to -3.1) Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42246672/

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Secukinumab is indexed as Monoclonal antibody with IL-17A biology and a global stage of Approved. The asset profile lists Novartis Pharma AG as an originator or developer.

Peking University Third Hospital is indexed in China with the website http://www.puh3.net.cn. Operates as a clinic The record lists 16 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Secukinumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07704190
Protocol source: https://clinicaltrials.gov/study/NCT07704190
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Secukinumab in Diabetes Mellitus, Type 2 is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Time to First Occurrence of 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) and 2028-12-31 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP